Navigation Links
Prostate cancer more likely to return in blacks than whites, but the disease is not more aggressive
Date:10/9/2007

DURHAM, N.C. -- African-American men are more likely to have their prostate cancer return after treatment, but their disease is no more aggressive when it does recur than that of their white counterparts, according to a study led by Duke Prostate Center researchers.

Our study found that African-American men have a slightly higher risk of what is known as PSA recurrence, which is a blood test that indicates the presence of cancer based on the levels of a certain biomarker known as prostate-specific antigen, said Stephen Freedland, M.D., a urologist at Duke and senior researcher on the study. We were encouraged, however, to see that their disease is not necessarily more aggressive than that of white men, once it has recurred.

African-American men tend to have higher PSA levels at initial diagnosis of prostate cancer, as well, despite being diagnosed at younger ages. This suggests that there may be an underlying genetic and biologic component that predisposes African-American men to prostate disease, Freedland said, highlighting the need for black men to have prostate screening early and often.

The team's findings will be published in the November 15, 2007 print edition of the journal Cancer, but also appeared early in the journals September 17, 2007 online edition. The study was funded by the U.S. Department of Defense, the Prostate Cancer Research Program, the Department of Veterans Affairs, the National Institutes of Health, the Georgia Cancer Coalition and the American Urological Association Foundation.

The researchers studied the medical records of 953 white and 659 black men who were treated for prostate cancer between 1988 and 2006 at five medical centers that make up the Shared Equal Access Regional Cancer Hospital (SEARCH) database. All received surgery, called radical prostatectomy, to treat their cancer.

The team examined the relationship between race and the amount of time that lapsed between surgery and recurrence, as well as the level of PSA found in the blood of the patients, Freedland said.

We found that African-American men were 28 percent more likely to experience a disease recurrence, said Robert Hamilton, M.D., a urology resident at the University of Toronto and former research fellow at Duke, and lead author on the publication. But when we compared the men who had experienced recurrence, we found that the aggressiveness of the disease was similar across the racial groups.

Although African-Americans may be more likely to see their disease return after treatment, this study points to a trend toward better screening and earlier detection among black men, Freedland said.

We did find that black men were diagnosed at younger ages and had higher PSA levels, but the fact that their disease seemed to be no more aggressive than that of their white counterparts was encouraging, he said. Earlier studies showed that black men had more aggressive disease at the time of diagnosis than other races, suggesting that their tumors were being discovered at more advanced stages.

Screening has apparently improved, but this study paves the way for more work aimed at developing preventive and treatment strategies directed at these genetic and biologic differences, Freedland said.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
3. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
4. Better prostate cancer detection
5. Protective effects of tomatoes in prostate cancer
6. Early detection of prostate cancer
7. Prevention of Prostate Cancer
8. Low grade prostate cancer may be treated with mild treatment
9. British MPs Say Prostate Cancer Receives Low Priority in the NHS
10. Diagnosing Prostate Cancer is Harder in Obese Individuals
11. Fingerprinting prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... Centennial, CO (PRWEB) , ... August 20, 2017 , ... ... in the same household? If so, you may be interested in participating in ... The purpose of this research is to understand more about the relational aspects of ...
(Date:8/19/2017)... York, New York (PRWEB) , ... August 19, ... ... Street Health has announced that it is the first organization with pending recognition ... CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live video ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners ... Orlando location as an interventional pain management physician. He brings a wealth of ... of migraine headaches, and significant experience in spinal cord stimulation for chronic pain. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology: